# Stephen A. Boorjian

Source: https://onco.cc/people/stephen-boorjian/  
OnCo record `stephen-boorjian` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mayo Clinic urologist who led the trial of nadofaragene firadenovec, the first gene therapy approved for bladder cancer that no longer responds to BCG.

## Summary

Stephen Boorjian chairs the department of urology at Mayo Clinic in Rochester. He was first author of the 2021 Lancet Oncology report of the phase 3 trial of intravesical nadofaragene firadenovec, an adenoviral vector delivering the interferon alfa-2b gene, in BCG-unresponsive non-muscle-invasive bladder cancer; about half of patients with carcinoma in situ had a complete response, the basis of the first gene therapy approval in bladder cancer. He also publishes on outcomes after cystectomy and nephrectomy.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: urothelial; gene-therapy; surgery; trialist
- Role: Chair of Urology, Mayo Clinic
- Specialisms: Bladder cancer; Intravesical therapy; Urological surgery outcomes

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/)
- institutions: [Mayo Clinic](https://onco.cc/institutions/mayo-clinic/)
- key papers: [Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-nadofaragene-firadenovec-lancet-oncol-2021/)

---
JSON: https://onco.cc/api/v1/entities/stephen-boorjian.json